Compare ALBT & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALBT | PPCB |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.7M |
| IPO Year | N/A | N/A |
| Metric | ALBT | PPCB |
|---|---|---|
| Price | $0.88 | $0.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 151.4K | ★ 3.2M |
| Earning Date | 03-30-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,611,940.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.16 |
| 52 Week High | $11.66 | $11.00 |
| Indicator | ALBT | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 34.63 |
| Support Level | $0.51 | $0.16 |
| Resistance Level | $0.91 | $0.24 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 76.64 | 29.09 |
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.